The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Schaffer David since 2018.
This trader's CIK number is 1692929.
At the time of last reporting, Schaffer David was the Officer of 4d Molecular Therapeutics Inc.. (stock ticker symbol FDMT).
Also see all insider trading activities at 4d Molecular Therapeutics Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | FDMT | 0 | $0 | 98,785 | $3,043,035 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2020 | QURE | 0 | $0 | 806 | $50,189 | 0 | $0 |
| 2019 | QURE | 0 | $0 | 8,710 | $268,210 | 0 | $0 |
| 2018 | QURE | 0 | $0 | 2,878 | $53,329 | 0 | $0 |
1. 4d Molecular Therapeutics Inc. (FDMT)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-10-20 | FDMT | Sale | 11,565 | 31.02 | 358,769 |
| 2021-10-21 | FDMT | Sale | 22,820 | 31.56 | 720,153 |
| 2021-10-22 | FDMT | Sale | 1,900 | 31.00 | 58,892 |
| 2021-09-29 | FDMT | Sale | 16,871 | 29.04 | 489,883 |
| 2021-09-30 | FDMT | Sale | 12,385 | 26.98 | 334,209 |
| 2021-09-28 | FDMT | Sale | 13,912 | 31.26 | 434,861 |
| 2021-09-27 | FDMT | Sale | 19,332 | 33.43 | 646,268 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-01-28 | QURE | Sale | 806 | 62.27 | 50,189 |
| 2019-01-28 | QURE | Sale | 1,210 | 31.31 | 37,885 |
| 2019-01-17 | QURE | Sale | 7,500 | 30.71 | 230,325 |
| 2018-01-29 | QURE | Sale | 2,878 | 18.53 | 53,329 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Schaffer David (Officer of 4d Molecular Therapeutics Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.